These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 29246900)

  • 1. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B.
    Miesbach W; Meijer K; Coppens M; Kampmann P; Klamroth R; Schutgens R; Tangelder M; Castaman G; Schwäble J; Bonig H; Seifried E; Cattaneo F; Meyer C; Leebeek FWG
    Blood; 2018 Mar; 131(9):1022-1031. PubMed ID: 29246900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy.
    von Drygalski A; Gomez E; Giermasz A; Castaman G; Key NS; Lattimore SU; Leebeek FWG; Miesbach WA; Recht M; Gut R; Dolmetsch R; Monahan PE; Le Quellec S; Pipe SW
    Blood Adv; 2023 Oct; 7(19):5671-5679. PubMed ID: 36490302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B.
    Shah J; Kim H; Sivamurthy K; Monahan PE; Fries M
    Curr Med Res Opin; 2023 Feb; 39(2):227-237. PubMed ID: 36285399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.
    George LA; Sullivan SK; Giermasz A; Rasko JEJ; Samelson-Jones BJ; Ducore J; Cuker A; Sullivan LM; Majumdar S; Teitel J; McGuinn CE; Ragni MV; Luk AY; Hui D; Wright JF; Chen Y; Liu Y; Wachtel K; Winters A; Tiefenbacher S; Arruda VR; van der Loo JCM; Zelenaia O; Takefman D; Carr ME; Couto LB; Anguela XM; High KA
    N Engl J Med; 2017 Dec; 377(23):2215-2227. PubMed ID: 29211678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.
    Pipe SW; Leebeek FWG; Recht M; Key NS; Castaman G; Miesbach W; Lattimore S; Peerlinck K; Van der Valk P; Coppens M; Kampmann P; Meijer K; O'Connell N; Pasi KJ; Hart DP; Kazmi R; Astermark J; Hermans CRJR; Klamroth R; Lemons R; Visweshwar N; von Drygalski A; Young G; Crary SE; Escobar M; Gomez E; Kruse-Jarres R; Quon DV; Symington E; Wang M; Wheeler AP; Gut R; Liu YP; Dolmetsch RE; Cooper DL; Li Y; Goldstein B; Monahan PE
    N Engl J Med; 2023 Feb; 388(8):706-718. PubMed ID: 36812434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of factor IX gene therapy in hemophilia B.
    Nathwani AC; Reiss UM; Tuddenham EG; Rosales C; Chowdary P; McIntosh J; Della Peruta M; Lheriteau E; Patel N; Raj D; Riddell A; Pie J; Rangarajan S; Bevan D; Recht M; Shen YM; Halka KG; Basner-Tschakarjan E; Mingozzi F; High KA; Allay J; Kay MA; Ng CY; Zhou J; Cancio M; Morton CL; Gray JT; Srivastava D; Nienhuis AW; Davidoff AM
    N Engl J Med; 2014 Nov; 371(21):1994-2004. PubMed ID: 25409372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical Implications of Factor IX Gene Transfer for Individuals with Hemophilia B: A Clinical Perspective.
    Miesbach W; Sawyer EK
    Hum Gene Ther Clin Dev; 2018 Jun; 29(2):80-89. PubMed ID: 29624465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency).
    Sekayan T; Simmons DH; von Drygalski A
    Expert Opin Biol Ther; 2023; 23(12):1173-1184. PubMed ID: 37962325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced Factor IX Activity following Administration of AAV5-R338L "Padua" Factor IX versus AAV5 WT Human Factor IX in NHPs.
    Spronck EA; Liu YP; Lubelski J; Ehlert E; Gielen S; Montenegro-Miranda P; de Haan M; Nijmeijer B; Ferreira V; Petry H; van Deventer SJ
    Mol Ther Methods Clin Dev; 2019 Dec; 15():221-231. PubMed ID: 31709273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression.
    Konkle BA; Walsh CE; Escobar MA; Josephson NC; Young G; von Drygalski A; McPhee SWJ; Samulski RJ; Bilic I; de la Rosa M; Reipert BM; Rottensteiner H; Scheiflinger F; Chapin JC; Ewenstein B; Monahan PE
    Blood; 2021 Feb; 137(6):763-774. PubMed ID: 33067633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.
    Nathwani AC; Tuddenham EG; Rangarajan S; Rosales C; McIntosh J; Linch DC; Chowdary P; Riddell A; Pie AJ; Harrington C; O'Beirne J; Smith K; Pasi J; Glader B; Rustagi P; Ng CY; Kay MA; Zhou J; Spence Y; Morton CL; Allay J; Coleman J; Sleep S; Cunningham JM; Srivastava D; Basner-Tschakarjan E; Mingozzi F; High KA; Gray JT; Reiss UM; Nienhuis AW; Davidoff AM
    N Engl J Med; 2011 Dec; 365(25):2357-65. PubMed ID: 22149959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B.
    Arruda VR; Stedman HH; Haurigot V; Buchlis G; Baila S; Favaro P; Chen Y; Franck HG; Zhou S; Wright JF; Couto LB; Jiang H; Pierce GF; Bellinger DA; Mingozzi F; Nichols TC; High KA
    Blood; 2010 Jun; 115(23):4678-88. PubMed ID: 20335222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial.
    Xue F; Li H; Wu X; Liu W; Zhang F; Tang D; Chen Y; Wang W; Chi Y; Zheng J; Du Z; Jiang W; Zhong C; Wei J; Zhu P; Fu R; Liu X; Chen L; Pei X; Sun J; Cheng T; Yang R; Xiao X; Zhang L
    Lancet Haematol; 2022 Jul; 9(7):e504-e513. PubMed ID: 35598604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B.
    Von Drygalski A; Giermasz A; Castaman G; Key NS; Lattimore S; Leebeek FWG; Miesbach W; Recht M; Long A; Gut R; Sawyer EK; Pipe SW
    Blood Adv; 2019 Nov; 3(21):3241-3247. PubMed ID: 31698454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.
    Crudele JM; Finn JD; Siner JI; Martin NB; Niemeyer GP; Zhou S; Mingozzi F; Lothrop CD; Arruda VR
    Blood; 2015 Mar; 125(10):1553-61. PubMed ID: 25568350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.
    Ozelo MC; Mahlangu J; Pasi KJ; Giermasz A; Leavitt AD; Laffan M; Symington E; Quon DV; Wang JD; Peerlinck K; Pipe SW; Madan B; Key NS; Pierce GF; O'Mahony B; Kaczmarek R; Henshaw J; Lawal A; Jayaram K; Huang M; Yang X; Wong WY; Kim B;
    N Engl J Med; 2022 Mar; 386(11):1013-1025. PubMed ID: 35294811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemophilia Gene Therapy: Ready for Prime Time?
    VandenDriessche T; Chuah MK
    Hum Gene Ther; 2017 Nov; 28(11):1013-1023. PubMed ID: 28793786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral gene therapy for hemophilia B using chitosan-formulated FIX mutants.
    Quade-Lyssy P; Milanov P; Abriss D; Ungerer C; Königs C; Seifried E; Schüttrumpf J
    J Thromb Haemost; 2014 Jun; 12(6):932-42. PubMed ID: 24679056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.
    Pasi KJ; Rangarajan S; Mitchell N; Lester W; Symington E; Madan B; Laffan M; Russell CB; Li M; Pierce GF; Wong WY
    N Engl J Med; 2020 Jan; 382(1):29-40. PubMed ID: 31893514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.